A. Passardi

Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study

Background In the TRIBE2 study, molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progres...

T. Latiano ;

E. Tamburini ;

A. Passardi ;

Sara Lonardi ;

D. Santini ;

H. Lenz ;

A. Zaniboni ;

C. Antoniotti ;

G. Aprile ;

F. Marmorino ;

R. Bordonaro ;

G. Zucchelli ;

G. Fontanini ;

F. Corti ;

M. Korn ;

V. Conca ;

R. Moretto ;

A. Falcone ;

M. Giordano ;

C. Cremolini ;

S. Lonardj ;

C. Ugolini ;

06/30/2020

Background The AtezoTRIBE study demonstrated that the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab prolongs PFS of mCRC patients, but a clinically modest benefit was obse...

Kirk McGregor ;

F. Bergamo ;

S. Leonetti ;

L. Provenzano ;

S. Tamberi ;

M. Ramundo ;

Giampaolo Tortora ;

C. Antoniotti ;

C. Rasola ;

A. Boccaccino ;

D. Ross ;

V. Conca ;

T. Nielsen ;

M. Giordano ;

M. Varga ;

C. Cremolini ;

A. Passardi ;

R. Seitz ;

M. Ambrosini ;

L. Salvatore ;

07/02/2022

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study

AtezoTRIBE (NCT03721653) is a phase II randomized trial in which unresectable mCRC pts were randomized 1:2 to 1st-line FOLFOXIRI/bev [arm A] or FOLFOXIRI/bev/atezo [arm B]. Adding atezo t...

S. Tamberi ;

M. Bensi ;

I. Toma ;

M. De Grandis ;

M. Palermo ;

A. Cappetta ;

Sara Lonardi ;

A. Catteau ;

C. Antoniotti ;

L. Boni ;

F. Marmorino ;

J. Galon ;